

Rising Influenza Prevalence Boosts Vaccine Market Growth: Key Driver Transforming The Afluria Market In 2025

The Business Research Company's Afluria Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 17, 2025 /EINPresswire.com/ -- How Has the Afluria Market Grown Over Time?



- The Afluria market has experienced significant growth, expanding from \$XX million in 2024 to \$XX million in 2025.
- This increase reflects a Compound Annual Growth Rate (CAGR) of XX%.
- · Key drivers behind this expansion include:
- o Rising influenza cases, leading to higher vaccine demand.



Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!"

The Business Research Company

- o A growing elderly population, increasing the need for immunization.
- o Higher healthcare spending, improving access to vaccines.
- o Expanded public health campaigns, raising vaccine awareness.
- o Increased confidence in vaccine safety, reducing hesitancy.

Get Your Free Sample of The Afluria Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19861&type=smp

What Is the Future Outlook for the Afluria Market?

- The market is projected to continue its upward trajectory, reaching \$XX million by 2029.
- This growth is expected to be driven by a forecasted CAGR of XX%.
- Several factors will contribute to this expansion, including:
- o Strong government support, promoting influenza prevention programs.
- o Greater emphasis on preventive healthcare, encouraging vaccination uptake.
- o Efforts to combat vaccine hesitancy, ensuring higher immunization rates.

- o Improved healthcare infrastructure, expanding vaccine accessibility.
- o Rising income levels in emerging economies, boosting affordability and demand.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/afluria-global-market-report

What Is Driving Growth in the Afluria Market?

The growing prevalence of influenza is a primary factor fueling market expansion. The elderly and high-risk populations are particularly vulnerable, driving the demand for effective vaccination programs. Afluria, an influenza vaccine, plays a crucial role in stimulating immune responses and preventing flu-related complications.

A UK Health Security Agency report (November 2024) highlighted the urgency of influenza prevention, showing that flu positivity rates increased from 2% to 2.3% within a week, with the highest rates observed in children aged 5 to 14 years (5.1%).

How Is the Aging Population Impacting Market Growth?

The rising geriatric population (65+ years) is a major driver of vaccine demand. Older adults are more susceptible to flu-related complications, necessitating widespread vaccination programs. A House of Commons Library report (July 2024) projected that the UK's elderly population would rise from 12.7 million in 2022 (19% of the population) to 22.1 million (27%) by 2072, reinforcing the long-term demand for flu vaccines.

Who Are the Leading Players in the Afluria Market?

CSL Seqirus is a major industry leader, capitalizing on market opportunities to strengthen its position. The industry is also seeing a shift toward innovation, with companies focusing on nanosized particle-based vaccines to enhance efficacy, stability, and targeted delivery.

How Is the Afluria Market Segmented?

The market is categorized into several key segments:

- 1. By Formulation:
- o Pre-Filled Syringes
- o Multi-Dose Vials
- 2. By Indication:
- o Influenza Prevention
- 3. By Distribution Channel:
- o Hospitals and Clinics
- o Retail Pharmacies
- o Government Suppliers
- 4. By End User:
- o Pediatric Patients
- o Adult Patients
- Geriatric Patients

Which Regions Are Leading the Afluria Market?

- North America dominated the market in 2024 as the largest regional market.
- Asia-Pacific is expected to be the fastest-growing region during the forecast period.
- Other regions covered in the report include Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company: Influenza Diagnostic Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Influenza Vaccines Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Influenza Treatment Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Learn More About The Business Research Company

The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:

The Business Research Company

Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

YouTube: https://www.youtube.com/channel/UC24 fl0rV8cR5DxlCpgmyFQ

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info

Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/794549847

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.